Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12 (2019) Hofheinz R, Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al. Conference contribution Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019) Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al. Conference contribution Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial (2019) Fasching P, Quek RGW, Bhattacharyya H, Hurvitz SA, Rugo HS, Ettl J Conference contribution Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy (2019) Huang M, Qi CZ, Ramsey S, Briggs A, Zhao J, Haiderali A, Karantza V, et al. Conference contribution PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy (2019) Girard N, Mornex F, Christoph DC, Fietkau R, Filippi AR, Field J, Garrido Lopez P, et al. Conference contribution EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, et al. Journal article MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018) Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, Nagtegaal ID, et al. Conference contribution